Browsing by Publisher "Elsevier Doyma"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Drug allergy in tertiary care in Turkey: Results of a national survey. The ADAPT study: Adult drug allergy perception in Turkey
    (Elsevier Doyma, 2014) Çelik G.E.; Karakaya G.; Öztürk A.B.; Gelincik A.; Abadoğlu T.; Sin A.; Damadoğlu E.; Yilmaz T.I.; Demirtürk M.; Dursun B.; Özdemir S.K.; Çelikel S.; Değirmenci P.; Bozkurt B.; Göksel T.; Erkekol F.; Aydin T.; Kavut A.B.; Kirmaz C.; Kalpaklioğlu F.; Büyüköztürk S.; Kalyoncu F.
    Background: No data are available on the incidence of drug hypersensitivity (DH) reactions in outpatient settings of tertiary allergy/immunology clinics. Our aims were to document the frequency of outpatient hospital admissions due to DH reactions to allergy/immunology clinics in adults and the management of these reactions in real life. We also investigated whether drug allergy affected social and medical behaviours of the patients. Methods: This multi-centre study was performed for one year with the participation of 11 out of 16 tertiary allergy/clinical immunology clinics in Turkey. The study group consisted of the patients with DH reactions. Results of a questionnaire including drug reactions and management were recorded. Results: Among 54,863 patients, 1000 patients with DH were enrolled with a median of 2.1% of all admissions. In real life conditions, the majority of approaches were performed for finding safe alternatives (65.5%; 1102 out of 1683) with 11.7% positivity. Diagnostic procedures were positive in 27% (154/581) of the patients. The majority of the patients had higher VAS scores for anxiety. A total of 250 subjects (25%) reported that they delayed some medical procedures because of DH. Conclusion: Our results documented the frequency of admissions due to DH reactions to allergy/clinical immunology clinics for the first time. Although physicians mostly preferred to perform drug tests in order to find safe alternatives, considering the fact that DH was confirmed in 27% of the patients, use of diagnostic tests should be encouraged, if no contraindication exists in order to avoid mislabelling patients as DH. © 2013 SEICAP.
  • No Thumbnail Available
    Item
    Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma
    (Elsevier Doyma, 2017) Asher I.; Haahtela T.; Selroos O.; Ellwood P.; Ellwood E.; Billo N.E.; Bissell K.; Chiang C.-Y.; El Sony A.; García-Marcos L.; Mallol J.; Marks G.B.; Pearce N.; Strachan D.; Priftanji A.; Benhabylès B.; Boukari R.; Castracane F.A.; Gómez M.; Salmun N.; Baghdasaryan A.; Burgess S.; Mattes J.; Tai A.; Haidinger G.; Riedler J.; Shpakou A.; Weyler J.; Gninafon M.; Aguirre de Abruzzese J.; Domuz S.; Brandão H.V.; Camargos P.A.M.; de Britto M.; Fischer G.B.; Kuschnir F.C.; Menezes A.M.; Porto Neto A.C.; Rosário N.; Solé D.; Wandalsen N.F.; Mustakov T.B.; Birba E.; Mbatchou Ngahane B.H.; Pefura Yone E.W.; Rennie D.C.; To T.; Standring P.; Calvo Gil M.A.; Chen Y.-Z.; Kan X.; Lin Y.; Garcia E.; Niederbacher J.; Ordoñez G.A.; Kabengele Obel B.; Soto-Quirós M.E.; Banac S.; Yiallouros P.; Lochte L.; Barba S.; Cooper P.; El Falaki M.; Mokhtar A.; Figueroa Colorado M.; Berihu A.; Weihe P.; Lal V.A.; Mäkelä M.; Annesi-Maesano I.; Charpin D.; Raherison C.; Gotua M.; von Mutius E.; Addo-Yobo E.O.; Clement N.F.; Gratziou C.; Tsanakas J.; Akpinar-Elci M.; Lai C.K.W.; Novák Z.; Awasthi S.; Ilangho R.; Maitra A.; Mukherjee M.; Pai U.A.; Pherwani A.V.; Reddy B.K.; Sabir M.; Sharma S.K.; Singh V.; Singh M.; Sukumaran T.U.; Varkki S.; Kartasasmita C.B.; Cheraghi M.; Karimi M.; Masjedi M.-R.; Manning P.; Shohat T.; Bonini S.; Forastiere F.; La Grutta S.; Petronio M.G.; Piffer S.; Kahwa E.; Odajima H.; Yoshihara S.; Abu-Ekteish F.; Al Omari O.; Amukoye E.I.; Esamai F.O.; Hong S.-J.; Neziri-Ahmetaj L.; Al-Momen J.A.; Svabe V.; Shenkada M.; Vlaski E.; Mortimer K.; de Bruyne J.; Toloba Y.; Montefort S.; Del-Río-navarro B.E.; García-Almaráz R.; González-Díaz S.N.; Hernández-Colín D.D.; Jiménez González C.A.; Mérida-Palacio J.V.; Brunekreef B.; Currie S.; Douwes J.; Graham D.; Hancox R.; Moyes C.; Pattemore P.; Cordero Rizo M.Z.; Erhabor G.E.; Falade A.; Garba Ilah B.; Hammangabdo A.; Onyia N.; Pulu M.; Nystad W.; Al-Rawas O.; Yusuf M.O.; Watson B.M.; El Sharif N.; Cukier G.; Checkley W.; Chiarella P.; Pagcatipunan R.; Lis G.; Morais-Almeida M.; Deleanu D.; Kamaltynova E.; Kondiurina E.G.; Esera-Tulifau L.; Al-Ghamdi B.R.; Yousef A.; Toure N.O.; Hadnadjev M.; Višnjevac D.; Zivkovic Z.; Fadlu-Deen G.; Goh D.Y.T.; Masekala R.; Voyi K.; Zar H.J.; Arnedo-Pena A.; Busquets R.M.; Carvajal-Urueña I.; González Díaz C.; Korta Murua J.; López-Silvarrey Varela A.; Luna-Paredes C.; Morales-Suárez-varela M.; Praena-Crespo M.; Rabadán-Asensio A.; Wärnberg J.; Gunasekera K.D.; Kudagammana S.T.; Hassanain S.; Mohammad Y.; Guo Y.L.; Huang J.-L.; Laoaraya M.; Phumethum S.; Teeratakulpisarn J.; Vichyanond P.; Anderson S.; Tidjani O.; Iosefa T.; Aho G.; Dookeeram D.; Hamzaoui A.; Yorgancioğlu A.; Ituaso-Conway N.; Worodria W.; Fedortsiv O.; Mahboub B.; Mansur A.H.; Doshi R.P.; Redding G.J.; Yeatts K.; Valentin-Rostan M.; Harrison G.; Le L.T.T.; Wa Somwe S.; Manangazira P.
    Background Several countries or regions within countries have an effective national asthma strategy resulting in a reduction of the large burden of asthma to individuals and society. There has been no systematic appraisal of the extent of national asthma strategies in the world. Methods The Global Asthma Network (GAN) undertook an email survey of 276 Principal Investigators of GAN centres in 120 countries, in 2013–2014. One of the questions was: “Has a national asthma strategy been developed in your country for the next five years? For children? For adults?”. Results Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%) reported having a national asthma strategy for children and 24 (21.4%) for adults; 22 (19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at least one age group. In countries with a high prevalence of current wheeze, strategies were significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%) respectively, p < 0.001). Interpretation In 25% countries a national asthma strategy was reported. A large reduction in the global burden of asthma could be potentially achieved if more countries had an effective asthma strategy. © 2017 SEICAP
  • No Thumbnail Available
    Item
    Prognosis of hospitalized patients with community-acquired pneumonia
    (Elsevier Doyma, 2018) Tokgoz Akyil F.; Yalcinsoy M.; Hazar A.; Cilli A.; Celenk B.; Kilic O.; Sayiner A.; Kokturk N.; Sakar Coskun A.; Filiz A.; Cakir Edis E.
    Introduction: The long-term prognosis of patients with community-acquired pneumonia (CAP) has attracted increasing interest in recent years. The objective of the present study is to investigate the short and long-term outcomes in hospitalized patients with CAP and to identify the predictive factors associated with mortality. Patients and methods: The study was designed as a retrospective, multicenter, observational study. Hospitalized patients with CAP, as recorded in the pneumonia database of the Turkish Thoracic Society between 2011 and 2013, were included. Short-term mortality was defined as 30-day mortality and long-term mortality was assessed from those who survived 30 days. Predictive factors for short- and long-term mortality were analyzed. Results: The study included 785 patients, 68% of whom were male and the mean age was 67 ± 16 (18–92). The median duration of follow-up was 61.2 ± 11.8 (37–90) months. Thirty-day mortality was 9.2% and the median survival of patients surviving 30 days was 62.8 ± 4.4 months. Multivariate analysis revealed that advanced age, the absence of fever, a higher Charlson comorbidity score, higher blood urea nitrogen (BUN)/albumin ratios and lower alanine aminotransferase (ALT) levels were all predictors of long-term mortality. Conclusion: Long-term mortality following hospitalization for CAP is high. Charlson score and lack of fever are potential indicators for decreased long-term survival. As novel parameters, baseline BUN/albumin ratios and ALT levels are significantly associated with late mortality. Further interventions and closer monitoring are necessary for such subgroups of patients. © 2017 Sociedade Portuguesa de Pneumologia
  • No Thumbnail Available
    Item
    Does atopy affect the course of viral pneumonia?
    (Elsevier Doyma, 2018) Erdem S.B.; Can D.; Girit S.; Çatal F.; Şen V.; Pekcan S.; Yüksel H.; Bingöl A.; Bostancı I.; Erge D.; Ersu R.
    Background: The presence of atopy is considered as a risk factor for severe respiratory symptoms in children. The objective of this study was to examine the effect of atopy on the course of disease in children hospitalised with viral pneumonia. Methods: Children between the ages of 1 and 6 years hospitalised due to viral pneumonia between the years of 2013 and 2016 were included to this multicentre study. Patients were classified into two groups as mild–moderate and severe according to the course of pneumonia. Presence of atopy was evaluated with skin prick tests. Groups were compared to evaluate the risk factors associated with severe viral pneumonia. Results: A total of 280 patients from nine centres were included in the study. Of these patients, 163 (58.2%) were male. Respiratory syncytial virus (29.7%), Influenza A (20.5%), rhinovirus (18.9%), adenovirus (10%), human metapneumovirus (8%), parainfluenza (5.2%), coronavirus (6%), and bocavirus (1.6%) were isolated from respiratory samples. Eighty-five (30.4%) children had severe pneumonia. Atopic sensitisation was found in 21.4% of the patients. Ever wheezing (RR: 1.6, 95% CI: 1.1–2.4), parental asthma (RR: 1.5, 95% CI: 1.1–2.2), other allergic diseases in the family (RR: 1.8, 95% CI: 1.2–2.9) and environmental tobacco smoke (RR: 1.6, 95% CI: 1.1–3.5) were more common in the severe pneumonia group. Conclusions: When patients with mild–moderate pneumonia were compared to patients with severe pneumonia, frequency of atopy was not different between the two groups. However, parental asthma, ever wheezing and environmental tobacco smoke exposure are risk factors for severe viral pneumonia in children. © 2017 SEICAP